Rational modelling of the voltage-dependent K+ channel inactivation by aminopyridines

Biophysical Chemistry

Volumn 104, Issue 2, 2003, Pages 417-427

  Niño, Alfonso ^a   Muñoz Caro, Camelia ^a   Carbó Dorca, Ramón ^b   Gironés, Xavier ^b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

Author keywords

Activity model; Aminopyridines; K+ channel blocking; Molecular quantum similarity

Indexed keywords

2 AMINOPYRIDINE; 3 AMINOPYRIDINE; 3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; 4 AMINOQUINOLINE; AMINE; AMINOPYRIDINE; CATION; DRUG RECEPTOR; NITROGEN; POTASSIUM CHANNEL BLOCKING AGENT; PYRIDINE; VOLTAGE GATED POTASSIUM CHANNEL;

AGONIST; ARTICLE; DRUG ACTIVITY; ELECTRIC POTENTIAL; ENTROPY; HYDROGEN BOND; HYPOTHESIS; IN VITRO STUDY; MODEL; PARTITION COEFFICIENT; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTUM MECHANICS; REGRESSION ANALYSIS; THEORY; VALIDATION PROCESS;

EID: 0038825361     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-4622(03)00030-9     Document Type: Article

References (34)

1. Kirsch G.E., Narahashi T. 3,4-Diaminopyridine. A potent new potassium channel blocker. Biophys. J. 22:1978;507-512.
2. Molgó J., Lemeignan M., Peradejordi F., Lechat P. Effects présynaptiques des aminopyridines a la junction neuromusculaire de vertébrés. J. Pharmacol. (Paris). 16 (Suppl. II):1985;109-144.
3. Carlsson C., Rosen I., Nilsson E. Can 4-aminopyridine be used to reverse anaesthesia and muscle relaxation? Acta Anaesthesiol. Scand. 27:1993;87-90.
4. McEvoy K.M., Windebank A.J., Daube N.J.R., Low P.A. 3-4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 321:1989;1567-1571.
5. Schwid S.R., Petrie M.D., McDermott M.P., Tierney D.S., Maso D.H., Goodman A.D. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 48:1997;817-821.
6. Segal J.L., Brunnemann S.R. 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Pharmacotherapy. 17:1997;415-423.
7. Sellin L.C. The action of botulinum toxin at the neuromuscular junction. Med. Biol. 59:1981;11-20.
8. Davidson M., Zemishlany J.H., Mohs R.C., Horvath T.B., Powchik P., Blass J.P., et al. 4-Aminopyridine in the treatment of Alzheimer's disease. Biol. Psychiatry. 23:1988;485-490.
9. Wickelgren I. Animal studies raise hopes for spinal cord repair. Science. 297:2002;178-181.
10. Gillespie J.I., Hutter O.F. The actions of 4-aminopyridine on the delayed potassium current in skeletal muscle fibres. J. Physiol. (Lond.). 252:1975;70P-71P.
11. Molgó J., Lundh H., Thesleff S. Potency of 3, 4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Pharmacol. 61:1980;25-34.
12. Kirsch G.E., Narahashi T. Site of action and active form of aminopyridines in squid axon membranes. J. Pharmacol. Exp. Ther. 226:1983;174-179.
13. Molgó J., Lemeignan M., Lechat P., Peradejordi F. Increase in evoked transmitter release from motor nerve terminals by some amino N-heterocyclic compounds, I. Eur. J. Med. Chem. 20:1985;149-153.
14. + currents in rabbit Schwann cells. J. Physiol. 433:1991;183-205.
15. Choquet D., Korn H. Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes. J. Gen. Physiol. 99:1992;217-240.
16. Peradejordi F., Molgó J., Lemeignan M. Increase in evoked transmitter release from motor nerve terminals by some amino N-heterocyclic compounds. II. Eur. J. Med. Chem. 20:1985;155-161.
17. + channel blocking by aminopyridines. Biophys. Chem. 91:2001;49-60.
18. + channel blocking by aminopyridines. Biophys. Chem. 96:2002;1-14.
19. Carbó-Dorca R., Robert D., Amat L.I., Girones X., Besalú E. Molecular quantum similarity in QSAR and drug design. Lecture Notes in Chemistry. 73:2000;Springer-Verlag.
20. Molgó J., Lemeignan M., Lechat P. Effects of 4-aminopyridine at the frog neuromuscular junction. J. Pharmacol. Exp. Ther. 203:1977;653-663.
21. Lucas K. Applied Statistical Thermodynamics. 1991;Springer-Verlag.
22. Carbó R., Besalú E., Amat L.I., Fradera X. Quantum molecular similarity measures (QMSM) as a natural way leading towards a theoretical foundation of quantitative structure-properties relationships (QSPR). J. Math. Chem. 18:1995;237-246.
23. Carbó-Dorca R., Besalú E. Quantum theory of QSAR. Contributions to Science. 1:2000;399-422 Institut d'Estudis Catalans, Barcelona.
24. 2. J. Chem. Phys. 52:1970;5270-5284.
25. 2SAR) equation: extensions, nonlinear terms and generalizations within extended Hilbert-Sobolev spaces. Int. J. Quantum Chem. 88:2002;167-182.
26. Ponec R., Amat L., Carbó-Dorca R. Quantum similarity approach to LFER: substituent and solvent effects on the acidities of carboxylic acids. J. Phys. Org. Chem. 12:1999;447-454.
27. Carbó R., Leyda L., Arnau M. How similar is a molecule to another? An electron density measure of similarity between two electronic structures. Int. J. Quantum Chem. 17:1980;1185-1189.
28. Johnson R.A., Wichern D.W. Applied Multivariate Analysis. 5th: 2002;Prentice-Hall.
29. Amat L., Carbó-Dorca R. Quantum similarity measures under atomic shell approximation: first order density fitting using elementary Jacobi rotations. J. Comput. Chem. 18:1997;2023-2039.
30. Gironés X., Robert R., Carbó-Dorca R. TGSA: a molecular superposition program based on topo-geometrical considerations. J. Comput. Chem. 22:2001;255-263.
31. Small Stata for Windows 98/95/NT, Stata Corporation, 2000.
32. Dewar M.J.S. A Semiempirical Life. 1992;160-162 American Chemical Society.
33. Ryan M.D. Chapter 4. Effect of hydrogen bonding on molecular electrostatic potential. Smith D.A. Modeling the Hydrogen Bond, ACS Symposium series 569. 1994;American Chemical Society.
34. Ma J.C., Dougherty D.A. The cation-π interaction. Chem. Rev. 97:1997;1303-1324.